目的 观察芍药钩藤木耳汤治疗原发性三叉神经痛的临床疗效及安全性。方法 选取2016-03至2017-03在医院接受治疗的80例原发性三叉神经痛患者,其中40例采用卡马西平治疗作为对照组,另外40例采用芍药钩藤木耳汤治疗作为观察组,比较两组治疗效果及不良反应。结果 芍药钩藤木耳汤组有效率82.5%,总有效率72.5%。治疗前两组VAS评分及LSI-B评分无明显差异。治疗4周后芍药钩藤木耳汤组VAS评分(2.9±0.9)低于卡马西平组(3.2±0.8);芍药钩藤木耳汤组LSI-B评分(16.0±2.6)高于卡马西平组(13.6±3.3);卡马西平组的不良反应发生率(32.5%)高于芍药钩藤木耳汤组(17.5%)。结论 芍药钩藤木耳汤治疗原发性三叉神经痛VAS评分较卡马西平低,LSI-B高,不良反应少,效果优于卡马西平,是一种安全、有效的治疗方法。
Abstract
Objective To observe the clinical efficacy and safety of Shaoyaogoutengmuer Tang in the treatment of primary trigeminal neuralgia. Methods Eighty patients with primary trigeminal neuralgia who were treated in the hospital between March 2016 and March 2017 were selected. Forty of these cases were treated with carbamazepine (control group), and the rest were treated with Shaoyaogoutengmuer Tang (observation group). The therapeutic effects and adverse reactions were compared between the two groups. Results The effective rate of the Shaoyaogoutengmuer Tang group was 82.5%, compared with 72.5% in the control group.Eleven cases were regarded as invalid.There was no significant difference in VAS scores or LSI-B scores between the two groups before treatment. After treatment of 4 weeks, the VAS score of the Shaoyaogoutengmuer Tang group (2.9±0.9) was lower than that of the carbamazepine group (3.2±0.8), while the LSI-B score of the Shaoyaogoutengmuer Tang group (16.0±2.6) was higher than that of the carbamazepine group (13.6±3.3). Conclusions Shaoyaogoutengmuer Tang has a lower VAS score but a higher LSI-B score than carbamazepine in the treatment of primary trigeminal neuralgia. Shaoyaogoutengmuer Tang causes fewer adverse reactions and is superior to carbamazepine, which is a safe and effective treatment.
关键词
卡马西平 /
芍药钩藤木耳汤 /
原发性三叉神经痛 /
VAS评分 /
LSI-B
Key words
carbamazepine /
Shaoyaogoutengmuer Tang /
primary trigeminal neuralgia /
VAS score /
LSI-B
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ömer Fatih Sahin, Kiliç E T, Aksoy Y,et al. The importance of perfusion index monitoring in evaluating the efficacy of stellate ganglion blockage treatment in Raynaud’s disease[J]. Libyan J Med, 2018, 13(1): 1422666.
[2] Mukherjee A A, Kandhare A D, Bodhankar S L. Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO[J]. Ren Fail, 2018, 40(1): 107.
[3] 苏鸿年. 加巴喷丁与卡马西平治疗复发性三叉神经痛的疗效比较[J].实用中西医结合临床, 2018, 18(01): 124-125.
[4] 贾建平, 陈生弟. 神经病学[M].7版. 北京:人民卫生出版社,2007
[5] Maarbjerg S, Di S G, Bendtsen L, et al. Trigeminal neuralgia - diagnosis and treatment[J]. Cephalalgia, 2017, 37(7): 648-657.
[6] Di S G, La C S, Truini A, et al. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain[J]. Clin Neurophysiol, 2014, 15(1): 34.
[7] 蒋萍萍.加巴喷丁与卡马西平治疗原发性三叉神经痛对照研究[J]. 医学综述, 2014, 20(13): 2478-2479.
[8] Yu H Y, Liu M G, Liu D N, et al. Antinociceptive effects of systemic paeoniflorin on bee venom-induced various 'phenotypes' of nociception and hypersensitivity[J]. Pharmacol Biochem Behav, 2007, 88(2): 131-140.
[9] 苗艳平, 杨 晶.芍药化学成分和药理作用的研究及分析[J]. 世界最新医学信息文摘:连续型电子期刊, 2015, 15(59): 1-2.
[10] 侯 爵.芍药甘草汤治疗急性腰扭伤的疗效观察[D].北京:北京中医药大学, 2014.
[11] 王 丽,甄汉深,梁臣艳,等.古钩藤的研究概况[J].中国民族民间医药, 2017, 26(13): 64-67.
[12] 崔 莹.钩藤化学成分和药理活性研究进展[J].西安文理学院学报(自然科学版), 2015(4): 16-18.
[13] 江 芳, 郭 娜, 童文琴,等.钩藤属植物研究进展[J].海峡药学, 2017, 29(4): 5-13.
[14] 王 红.卡马西平联合氨酚曲马多对原发性三叉神经痛的治疗效果[J].河南医学研究,2018, 27(05): 850-851.
[15] 周 莹,于 敏,张 婷.原发性三叉神经痛患者行卡马西平联合多虑平治疗的临床价值[J].中国医药指南,2018,16(4): 143-144.
[16] 焦 洋,魏立明,邱 雯.三种中药制剂对卡马西平在小鼠体内药动学的影响[J].中药药理与临床,2014, 30(1): 81-85.
[17] 师丽波.卡马西平治疗三叉神经痛致头晕的可能发病机制研究[J].黑龙江医学,2017, 41(4): 337-338.
PDF(748 KB)
